Muscle &Amp; Nerve

• 

  Publication Venue For

  • Neuromuscular ultrasound standardized scanning techniques and protocols: Expert panel recommendations. 2023
  • Ultrasound-guided-electromyography in plegic muscle: Usefulness of nerve stimulation..  67:204-207. 2023
  • Single fiber electromyography and measuring jitter with concentric needle electrodes..  66:118-130. 2022
  • Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses..  66:39-49. 2022
  • Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy..  66:50-62. 2022
  • Single fiber EMG and measuring jitter with concentric needle electrodes. 2022
  • The neuromuscular fellowship portal and match..  65:640-645. 2022
  • Could posturography be a useful outcome measure for chronic inflammatory demyelinating polyneuropathy?.  65:7-9. 2022
  • Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis..  65:75-81. 2022
  • Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study..  64:662-669. 2021
  • What is the significance of gender difference in myasthenia gravis?.  64:515-516. 2021
  • Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19..  64:E18-E20. 2021
  • Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis..  64:385-387. 2021
  • COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis..  64:E13-E15. 2021
  • Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)..  64:270-276. 2021
  • Quantitative muscle echointensity: A practical approach using ultrasound to evaluate children with suspected neuromuscular disorders..  64:6-7. 2021
  • Neuromuscular ultrasound competency assessment: Consensus-based survey..  63:651-656. 2021
  • Reduced plasmablast frequency is associated with seronegative myasthenia gravis..  63:577-585. 2021
  • Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis..  63:357-364. 2021
  • The Duke myasthenia gravis clinic registry: I. Description and demographics..  63:209-216. 2021
  • Single-institutional reference values for concentric needle jitter analysis using the extrapolated reference values procedure: Comparison to published reference values..  63:113-116. 2021
  • Fatigue in chronic inflammatory demyelinating polyneuropathy..  62:673-680. 2020
  • Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities..  62:182-186. 2020
  • AANEM - IFCN Glossary of Terms in Neuromuscular Electrodiagnostic Medicine and Ultrasound..  62:10-12. 2020
  • Spinal muscular atrophy care in the COVID-19 pandemic era..  62:46-49. 2020
  • The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic..  62:41-45. 2020
  • Emerging technologies in neuromuscular ultrasound..  61:719-725. 2020
  • A step toward the future of seamless measurement with wearable sensors in pediatric populations with neuromuscular diseases..  61:265-267. 2020
  • Guidelines for neuromuscular ultrasound training..  60:361-366. 2019
  • Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia..  60:292-298. 2019
  • 4-Aminopyridine attenuates muscle atrophy after sciatic nerve crush injury in mice..  60:192-201. 2019
  • ULTRASOUND IN THE DIAGNOSIS AND MONITORING OF AMYOTROPHIC LATERAL SCLEROSIS: A REVIEW..  60:114-123. 2019
  • Long-term safety and efficacy of eculizumab in generalized myasthenia gravis..  60:14-24. 2019
  • Neuromuscular transmission in myopathies..  60:E8. 2019
  • Repetitive nerve stimulation testing in myasthenic crisis..  59:528-530. 2019
  • Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis..  59:404-410. 2019
  • Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial..  59:201-207. 2019
  • On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness..  58:743-744. 2018
  • Reply..  58:E31-E32. 2018
  • Sonographic similarities of inclusion body myositis and myotonic dystrophy..  58:E25-E26. 2018
  • Neuromuscular ultrasound findings in eosinophilic fasciitis: A case series and literature review..  58:E15-E18. 2018
  • Reply..  57:E130-E131. 2018
  • 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia..  57:561-568. 2018
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab..  57:E120-E121. 2018
  • B cells in the pathophysiology of myasthenia gravis..  57:172-184. 2018
  • Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I..  57:193-199. 2018
  • Neuromuscular Ultrasound: A call for training and education..  57:168-169. 2018
  • Reliability of the triple-timed up-and-go test..  57:136-139. 2018
  • The extrapolated reference values procedure: Theory, algorithm, and results in patients and control subjects..  57:90-95. 2018
  • Advancing neuromuscular ultrasound through research: Finding common sound..  56:375-378. 2017
  • Marked clinical and jitter improvement after eculizumab in refractory myasthenia..  56:E16-E18. 2017
  • QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis..  56:328-330. 2017
  • Does change in neuromuscular jitter predict or correlate with clinical change in MG?.  56:45-50. 2017
  • Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy..  55:366-372. 2017
  • Factors affecting outcome in myasthenia gravis..  54:1041-1049. 2016
  • International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r..  54:1015-1022. 2016
  • Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis..  54:658-665. 2016
  • Ultrasound in EMG-Guided Biopsies: A Prospective, Randomized Pilot Trial..  54:786-788. 2016
  • Assessment of obstetric brachial plexus injury with preoperative ultrasound..  53:946-950. 2016
  • Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument..  54:9-17. 2016
  • Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial..  53:363-369. 2016
  • Lambert-Eaton myasthenia?.  53:495. 2016
  • Multifocal motor neuropathy: 30 years from onset to diagnosis..  53:490-491. 2016
  • Reference values for jitter recorded by concentric needle electrodes in healthy controls: A multicenter study..  53:351-362. 2016
  • Adaptive immune response to therapy in hmgcr autoantibody myopathy..  53:313-317. 2016
  • Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine..  53:165-168. 2016
  • Stimulated jitter in infant botulism..  52:691-692. 2015
  • Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis..  52:211-215. 2015
  • Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer..  52:307-308. 2015
  • Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease..  51:722-730. 2015
  • Quantitative assessment of lingual strength in late-onset Pompe disease..  51:731-735. 2015
  • Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States..  51:635-637. 2015
  • Ultrasound of cervical roots and brachial plexus in neonates..  51:626. 2015
  • Ataluren treatment of patients with nonsense mutation dystrophinopathy..  50:477-487. 2014
  • Proximal median neuropathy caused by surgical manipulation of Masson tumor..  50:617-618. 2014
  • Blood-based diagnostic testing for Pompe disease: consistency between GAA enzyme activity in dried blood spots and GAA gene sequencing results..  49:775-776. 2014
  • Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?.  49:483-486. 2014
  • Truncating CLCN1 mutations in myotonia congenita: variable patterns of inheritance..  49:593-600. 2014
  • Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?.  49:30-34. 2014
  • Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment..  48:992-993. 2013
  • Ultrasound diagnosis of bony nerve entrapment: case series and literature review..  48:445-450. 2013
  • Generating color-coded anatomic muscle maps for correlation of quantitative magnetic resonance imaging analysis with clinical examination in neuromuscular disorders..  48:293-295. 2013
  • A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis..  48:76-84. 2013
  • Neuromuscular ultrasound in polyneuropathies and motor neuron disease..  47:790-804. 2013
  • Basilar artery aneurysm: a new finding in classic infantile Pompe disease..  47:613-615. 2013
  • Reporting the results of diagnostic neuromuscular ultrasound: an educational report..  47:608-610. 2013
  • Measuring jitter with concentric needle electrodes..  47:317-318. 2013
  • Nerve ultrasound in diabetic polyneuropathy: correlation with clinical characteristics and electrodiagnostic testing..  47:379-384. 2013
  • Polysialic acid expression is not necessary for motor neuron target selectivity..  47:364-371. 2013
  • A retrospective study of complications of therapeutic plasma exchange in myasthenia..  47:170-176. 2013
  • Reply: To PMID 22581550..  47:145-146. 2013
  • Median nerve ultrasound as a screening tool in carpal tunnel syndrome: correlation of cross-sectional area measures with electrodiagnostic abnormality..  46:871-878. 2012
  • Muscle force development after low-frequency magnetic burst stimulation in dogs..  46:954-956. 2012
  • Evidence-based guideline: neuromuscular ultrasound for the diagnosis of carpal tunnel syndrome..  46:287-293. 2012
  • Diaphragm pacing in amyotrophic lateral sclerosis: a literature review..  46:1-8. 2012
  • Psychometric evaluation of the myasthenia gravis composite using Rasch analysis..  45:820-825. 2012
  • Recommendations for myasthenia gravis clinical trials..  45:909-917. 2012
  • Exercise and Duchenne muscular dystrophy: where we have been and where we need to go..  45:746-751. 2012
  • Estimated cost of treating myasthenia gravis in an insured U.S. population..  45:363-366. 2012
  • How common is misdiagnosis in late-onset Pompe disease?.  45:301-302. 2012
  • p38γ activity is required for maintenance of slow skeletal muscle size..  45:266-273. 2012
  • Cost analysis of myasthenia gravis from a large U.S. insurance database..  44:907-911. 2011
  • Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation..  44:897-901. 2011
  • Effect of transducer frequency on muscle luminosity ratio..  44:612-613. 2011
  • Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts..  44:36-40. 2011
  • Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity..  43:665-670. 2011
  • Evaluation of muscles affected by myositis using magnetic resonance elastography..  43:585-590. 2011
  • The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis..  43:14-18. 2011
  • Pseudometabolic presentation of dystrophinopathy due to a missense mutation..  42:975-979. 2010
  • Two children with "dropped head" syndrome due to lamin A/C mutations..  42:839-841. 2010
  • Qualifications for practitioners of neuromuscular ultrasound: position statement of the American Association of Neuromuscular and Electrodiagnostic Medicine..  42:442-444. 2010
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy..  41:746-750. 2010
  • Immunopathogenesis of juvenile dermatomyositis..  41:581-592. 2010
  • Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients..  41:593-598. 2010
  • Construct and concurrent validation of the MG-QOL15 in the practice setting..  41:219-226. 2010
  • Pregnancy in MuSK-positive myasthenia gravis: A single-center case series. 2023
  • The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes. 2023
  • Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. 2014